DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer.
Astellas will provide research support and retain the option to obtain from Dana-Farber an exclusive, worldwide license to novel K-Ras inhibitors obtained from the collaboration. Astellas would then conduct further research, development and commercialization.
Nathanael Gray, of the Cancer Biology Department at Dana-Farber and professor at Harvard Medical School, will lead this collaborative research. His laboratory and the Dana-Farber Medicinal Chemistry Core will be joined by the laboratories of Pasi Jänne, and Kwok-Kin Wong, of the Thoracic Oncology Program and co-directors of the Belfer Institute for Applied Cancer Science at Dana-Farber and Professors at Harvard Medical School.
